All In Biotech

Drug Trial Radar · NCT06956690

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Hummingbird BioscienceIndustry
Sponsor type
Industry
First posted
May 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalating doses of HMBD-501. The results of the dose escalation will determine the RP2D and dosing schedule of HMBD-501 to be administered in the Phase 2 part of the study. The primary objective of Phase 2 is to evaluate the preliminary clinical efficacy of HMBD-501 in dose expansion cohorts.

Conditions

  • Melanoma (Skin)
  • Non Small Cell Lung Cancer
  • Breast Cancer

Interventions

  • ENV-501Biological

    ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose Escalation): Frequency of treatment-emergent adverse eventsTime frame: through study completion, an average of 6 months
  2. Phase 2 (Dose Expansion): Objective Response Rate (ORR)Time frame: through study completion, an average of 6 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Indianapolis, Indiana · Recruiting

  • Research Site

    Farmington Hills, Michigan · Recruiting

  • Research Site

    Dallas, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    Campbelltown, New South Wales, Australia · Withdrawn

  • Research Site

    Miranda, New South Wales, Australia · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.